Summary:
- Fore Biotherapeutics, a biotherapeutics company based in Philadelphia, secured $38M in Series D-2 financing to develop targeted cancer therapies.
- The funding round was supported by various investors, including R One, Medicxi, and Novartis Venture Fund.
- Fore Biotherapeutics aims to advance its Forte Master Protocol, a global Phase 2 clinical trial evaluating plixorafenib in different patient populations.
Article:
In a recent development, Fore Biotherapeutics, a Philadelphia-based biotherapeutics company, announced the successful completion of a $38M Series D-2 financing round. The company, dedicated to developing targeted therapies for cancer patients, received backing from prominent investors such as R One, Medicxi, OrbiMed, and Novartis Venture Fund. This funding will enable Fore Biotherapeutics to progress with its registration-intended Forte Master Protocol, a global Phase 2 clinical trial that includes four sub-protocol baskets evaluating plixorafenib in distinct patient populations.
Led by CEO William Hinshaw, Fore Biotherapeutics focuses on advancing new treatments for patients with challenging-to-treat cancers. Their lead asset, plixorafenib (FORE8394), a V600 and non-V600 BRAF inhibitor, has shown promising efficacy signals across various tumor types with a manageable safety profile. The company is currently enrolling patients in the FORTE global registrational basket trial to support three distinct indications.
The $38M raised in the Series D-2 financing adds to the $75M previously secured in the Series D and D-1 rounds, bringing the total funding to $113M. This significant investment underscores the confidence investors have in Fore Biotherapeutics’ innovative approach to developing targeted oncology treatments that aim to improve patient outcomes.
Stay tuned for more updates on Fore Biotherapeutics as they continue to make strides in the field of biotherapeutics and cancer therapy.
FinSMEs
23/05/2025
